ライフサイエンスコーパス: pneumococcal meningitis

1 means they influence the pathophysiology of pneumococcal meningitis.

2 e associated with morbidity and mortality of pneumococcal meningitis.

3 long-term hearing function in a rat model of pneumococcal meningitis.

4 IgR and PECAM-1 has the potential to prevent pneumococcal meningitis.

5 in CSF specimens from patients and mice with pneumococcal meningitis.

6 ammation and potential therapeutic target in pneumococcal meningitis.

7 ions for use of adjunctive dexamethasone for pneumococcal meningitis.

8 be associated with outcome in patients with pneumococcal meningitis.

9 t of CNS inflammation in an in vivo model of pneumococcal meningitis.

10 We identified 1379 cases of pneumococcal meningitis.

11 in play crucial roles in the pathogenesis of pneumococcal meningitis.

12 is plays in neuronal death in the context of pneumococcal meningitis.

13 rognosis for patients, especially those with pneumococcal meningitis.

14 e to the neuropathology commonly observed in pneumococcal meningitis.

15 en and adults with haemophilus meningitis or pneumococcal meningitis.

16 uggesting new neuroprotective strategies for pneumococcal meningitis.

17 ironment needed to establish nonhematogenous pneumococcal meningitis.

18 ebrospinal fluid compartment in experimental pneumococcal meningitis.

19 fatality was 8% (25/329) and was higher for pneumococcal meningitis (5/26 [19%]) than GBS meningitis

20 in the cerebrospinal fluid of patients with pneumococcal meningitis (6.8 to 3,900 ng of muramic acid

21 lysis was restricted to patients with proven pneumococcal meningitis (68 of 129 patients receiving co

22 genetic marker of morbidity and mortality of pneumococcal meningitis and also suggests a potential ro

23 In conclusion, pneumococcal meningitis and herpes simplex encephalitis

24 tive, nationwide cohort of 405 patients with pneumococcal meningitis and in 329 controls matched for

25 multaneous in vivo biophotonic monitoring of pneumococcal meningitis and the accompanying neuronal in

26 5 years with H influenzae, meningococcal and pneumococcal meningitis, and septicaemia.

27 The mortality and morbidity of pneumococcal meningitis are still devastating, and resul

28 association study in 469 community-acquired pneumococcal meningitis cases and 2072 population-based

29 As apoptosis drives neuronal loss in pneumococcal meningitis, caspase inhibitors might provid

30 Mortality from pneumococcal meningitis decreased between 2005 (0.049 pe

31 reducing the incidence of hearing loss from pneumococcal meningitis, especially if therapy is instit

32 We examined trends in pneumococcal meningitis from 1998 through 2005 using act

33 Pneumococcal meningitis had the highest case fatality ra

34 Their role in the pathogenesis of pneumococcal meningitis has not been addressed.

35 Rates of pneumococcal meningitis have decreased among children an

36 llin-susceptible and cephalosporin-resistant pneumococcal meningitis in rabbits, staphylococcal and e

37 investigated the progression and outcome of pneumococcal meningitis in Rag1(-/-) mice lacking functi

38 To better understand the high incidence of pneumococcal meningitis in the African meningitis belt,

39 ective antibody seroprevalence in preventing pneumococcal meningitis in the meningitis belt requires

40 Despite a substantially higher historical pneumococcal meningitis incidence in Burkina Faso, the g

41 role played by pneumolysin and autolysin in pneumococcal meningitis is poorly understood.

42 Pneumococcal meningitis is the most frequent and critica

43 te vaccine (PCV7) in 2000, but its effect on pneumococcal meningitis is unclear.

44 Poor prognosis in Pneumococcal meningitis may be associated with high pneu

45 ubjects (controls, n = 10) and patients with pneumococcal meningitis (n = 20) was analyzed.

46 Patients with pneumococcal meningitis often die or have severe neurolo

47 y of being employed as a former patient with pneumococcal meningitis or herpes simplex encephalitis v

48 nt pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis (PM) in US children is unknown.

49 Hearing loss is an important sequela of pneumococcal meningitis (PM), occurring in up to 30% of

50 occurring in up to 30% of patients surviving pneumococcal meningitis (PM).

51 In experimental pneumococcal meningitis, pneumolysin colocalized with ap

52 te recent advances in antimicrobial therapy, pneumococcal meningitis remains a life-threatening disea

53 Pneumococcal meningitis remains a significant cause of m

54 Subgroup analysis on patients with pneumococcal meningitis showed similar results.

55 tween multiple variants in a gene region and pneumococcal meningitis susceptibility yielded one signi

56 der to find genetic variants associated with pneumococcal meningitis susceptibility.

57 rabbit model of hearing loss in experimental pneumococcal meningitis to evaluate the therapeutic effe

58 pectively) in the progression and outcome of pneumococcal meningitis, using Kaplan-Meier survival cur

59 Pneumococcal meningitis was diagnosed in 77% of patients

60 of brain biopsies from patients who died of pneumococcal meningitis, we observe that pneumococci col

61 Changes in the incidence of pneumococcal meningitis were assessed against baseline v

62 Two apparently linked fatal cases of pneumococcal meningitis were investigated.

63 st signals associated with susceptibility to pneumococcal meningitis were rs139064549 on chromosome 1

64 nctive steroid treatment is underutilized in pneumococcal meningitis, where it has shown to decrease

65 f all patients and in 39.3% of patients with pneumococcal meningitis, with an associated decrease in